UC Davis/NIH NeuroMab Facility-Administrative Supplement

 描述（由申请方提供）：已验证并优化用于哺乳动物脑（即NeuroMabs）的高质量、可靠和单特异性小鼠单克隆抗体（mAb）的可用性对神经科学研究的许多领域至关重要。对于大脑中表达的每种蛋白质，都需要有这样的试剂来进行生物化学和免疫组织化学研究，以便开始将来自基于基因组的方法的核酸序列信息与大脑中编码基因产物的功能联系起来。不幸的是，缺乏针对特定基因产物的抗体，或者缺乏特异性的抗体，可能会严重阻碍整个神经科学研究领域的发展，从而阻碍对神经疾病机制的理解。UC Davis/NIH NeuroMab Facility主要通过两种方式来满足这一未满足的需求：为NIH认为具有高优先级的目标生成NeuroMab，并以低成本非营利的方式将其分发给神经科学研究社区。来自加州大学戴维斯分校和各种NIH来源的种子基金允许我们在2005年创建我们的设施，在过去的九年里，我们已经开展了针对400多种脑蛋白的mAb项目，并产生了370多种NeuroMab的目录。通过我们的承包商Antibodies Incorporated（AI），我们以低成本向全球众多不同机构的数百名研究人员分发了超过44，500瓶NeuroMab，我们的最终用户在超过1500份原始研究出版物中引用了NeuroMab的使用。假设每100 μg纯化mAb的保守营利性价格为350美元，NeuroMab为最终用户及其各自的资助机构节省的非营利费用估计超过1250万美元。我们已经证明了自己是一个具有重要贡献的强大记录的机构，我们希望继续尽我们所能为神经科学研究人员服务。多年来，我们的设施对NIH及其使命的价值已经通过各种资助计划一次又一次地得到证明，最近的一次来自NIH主任的变革R 01计划。此外，NIH、加州大学董事会和AI的联合支持与合作使我们自2011年以来能够从NeuroMab的分配中收集项目收入，以支持未来的设施自给自足和新的mAb研发。然而，R 01转型资金和累计计划收入的组合不足以留住我们经验丰富的高级员工，使该设施以目前的生产力水平运行，并继续进行NINDS高度优先的项目。通过额外的R24资金保持NIH的大力支持将有助于保留我们宝贵的人力和技术资源，保护我们目前的加州大学戴维斯分校基础设施，并保持我们对版税和许可附加费的特殊保护，这些费用将不必要地提高NeuroMab的价格。

 DESCRIPTION (provided by applicant): The availability of high-quality, reliable and monospecific mouse monoclonal antibodies (mAbs) that have been validated and optimized for use in mammalian brain (i.e. NeuroMabs) is of utmost importance to many areas of neuroscience research. Having such reagents for each of the proteins expressed in the brain is necessary to undertake biochemical and immunohistochemical studies to begin to link the nucleic acid sequence information derived from genome-based approaches to the function of the encoded gene products in the brain. Unfortunately, the lack of antibodies against a particular gene product, or antibodies that lack specificity, can severely handicap an entire subfield of neuroscience research and thereby impede progress towards understanding the mechanisms that underlie neurological disease. The UC Davis/NIH NeuroMab Facility works towards this unmet need in two major ways: by generating NeuroMabs for targets that are deemed high-priority by NIH and by distributing them on a low-cost non-profit basis to the neuroscience research community. Seed funds from UC Davis and various NIH sources allowed for the creation of our Facility in 2005 and, over the past nine years, we have undertaken mAb projects against over 400 brain proteins and generated a catalog of over 370 NeuroMabs. Through our contractor Antibodies Incorporated (AI), we have distributed over 44,500 vials of NeuroMabs at low cost to hundreds of researchers at a multitude of different institutions worldwide and our end users have cited the use of NeuroMabs in over 1500 original research publications. Assuming a conservative for-profit price of $350 per 100 µg vial of purified mAb, an estimate of the NeuroMab non-profit savings to end users and their respective funding agencies is over $12.5 million. We have proven ourselves to be an establishment with a strong track record of important contributions and we wish to continue serving neuroscience researchers as best as we can. The worthiness of our Facility to the NIH and its mission has been demonstrated time and again through various funding initiatives over the years, most recently from the NIH Director's Transformative R01 Program. In addition, the combined support and cooperation of the NIH, the Regents of the University of California and AI have enabled us since 2011 to collect program income from the distribution of NeuroMabs to support future Facility self-sufficiency and new mAb research and development. However, the combination of the Transformative R01 funds and the accumulated program income is insufficient to hold onto our experienced senior staff, to keep the Facility running at its present-day level of productivity and to continue doing projects of high priority to NINDS. Maintaining strong support from NIH through additional R24 funding would be instrumental to retaining our valuable human and technological resources, preserving our current UC Davis infrastructure and keeping intact our exceptional protection from royalty and licensing surcharges that would unnecessarily raise the prices of NeuroMabs for our end users.